NM-3

NM-3 is an orally bioavailable isocoumarin derivative that functions as an angiogenesis inhibitor. Originally developed by EntreMed and later partnered with Sanofi (formerly Aventis), NM-3 was designed to treat advanced solid tumors by disrupting the formation of new blood vessels required for tumor growth and metastasis. Its mechanism involves inhibiting the proliferation and inducing apoptosis of endothelial cells, potentially by interfering with pro-angiogenic signaling pathways such as those involving vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Clinical development reached Phase I/II trials, where it was evaluated both as a monotherapy and in combination with cytotoxic agents like gemcitabine or paclitaxel, but development was ultimately discontinued.

Other names

2-(8-hydroxy-6-methoxy-1-oxo-1H-isochromen-3-yl)propionic acid